Site for PNOC027; A pilot trial of real time drug screening and genomic testing to determine an individualized treatment plan in children and young adults with relapsed medulloblastoma
Site for The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility of performing real-time drug screening on tissue taken during surgery, and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with medulloblastoma to receive the most effective and least toxic therapies currently available, and will pave the way for improved understanding and treatment of these tumors in the future.
Site for Registry of Asthma Patients Initiating
Site for Participant in this observational research study sponsored by Regeneron Pharmaceuticals, Inc., are being asked to participate because they are receiving treatment with dupilumab, since you are currently being treated for asthma by a study participating physician. The study is being done to characterize and collect long term data on patients 12 years and older with moderate to severe asthma, who receive treatment with dupilumab (also known as DUPIXENT®).
Site for Studies of Patients with Implanted Intracranial Electrodes
Site for The overall goals of this research protocol are 1) to better understand the function of cortical sites that are measured with scalp electrodes (electroencephalography, or EEG) and/or implanted intracranial electrodes (electrocorticography, or ECoG) and 2) to determine the most effective and safe testing methods, including cortical stimulation and passive EEG or ECoG recordings, for defining this cortical function so that post-operative neurological impairments are avoided.
Site for Understanding health disparities in Pakistani Bangladeshi and Asian Indian immigrants: the role of socio-cultural context acculturation and resilience resources - Mediators of Atherosclerosis in South Asians Living in America (MASALA) Study Expansion New York Site
Site for This protocol describes a mixed methods study that leverages the infrastructure of an ongoing MASALA study in Chicago and San Francisco to enroll 600 Bangladeshi and 250 Pakistani adults aged 40-84 years as part of a greater New York City cohort. These participants will be added to the 1,550 surviving participants already in MASALA for well-powered subgroup comparisons and ongoing follow-up. Participants will complete a physical exam and survey, provide biospecimens, and be followed longitudinally (12M, 24M) to complete surveys in order to identify how socio-cultural context, discrimination, acculturation strategies and resilience resources act as risk or protective factors explaining CVH disparities in Indian, Pakistani and Bangladeshi immigrants.
Site for WUH APOLLO TRIAL: Transcatheter Mitral Valve Replacement with the Medtronic Intrepid TMVR System in patients with severe symptomatic mitral regurgitation APOLLO Trial
Site for Multi-center, global, prospective, randomized, interventional, pre-market trial Subjects will be randomized on 1:1 basis to either TMVR with the Medtronic Intrepid™ TMVRSystem or to conventional mitral valve surgery.Subjects ineligible for randomization may be enrolled through a single-arm trial. Subjectsenrolled in the single-arm cohort will be assigned to TMVR with the Medtronic Intrepid™ TMVR System
Site for WUH TrialNet: NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETES
Site for The TrialNet Natural History Study of the Development of T1D is divided into Screening and Monitoring stages. Each stage will require separate informed consent for entry. Screening involves testing relatives of individuals with diabetes for the presence of islet autoantibodies. Individuals who have autoantibodies will be enrolled into the Monitoring stage (see Appendix Schedule of Assessments). The study will use a prospective cohort design.The algorithm below shows the flow of participants in the Screening and Monitoring stages. The Screening stage involves measurement of GAD65A, IA-2A, and mIAA, (with a positive result for any of these leading to measurement of ICA and ZnT8A) to determine whether the participant is eligible for the Monitoring stage. As additional diabetes-related autoantibodies are discovered and validated, they may also be included in Screening. Participants will be eligible for Monitoring if they have at least two positive autoantibodies on a Screening sample or at least one positive autoantibody on two separate Screening samples. Participants younger than 18 years old who are negative for all autoantibodies will be offered annual autoantibody rescreening until their 18th birthday. Participants 18 or older with a single positive autoantibody on the first Screening sample but no positive autoantibodies on a confirmatory test will be offered annual rescreening for two years.
Sjogren's Syndrome | NYU Langone Health
NYU Langone rheumatologists diagnose and treat Sjogren’s syndrome, an autoimmune disorder.
Skin & Cancer Unit | NYU Langone Health
NYU Langone’s Skin and Cancer Unit provides expert diagnostic and treatment services for virtually all skin diseases for patients of all ages.
Skin & Cosmetic Conditions | NYU Langone Health
NYU Langone dermatologists and plastic surgeons treat skin and cosmetic conditions in both adults and children.
Skin Autoimmune Disorder Services | NYU Langone Health
NYU Langone dermatologists specialize in treating autoimmune connective tissue diseases of the skin.